| Laboratory: | Clinical Biochemistry (AUTOMATED) |
| Test Name: |
APOLIPOPROTEIN B - (S) (P)
Test Code:
APB
|
| Clinical Information: |
Apolipoprotein B is not useful for the routine screening, diagnosis or treament of lipid disorders and it provides the same information as non-HDL cholesterol which is already part of the lipid profile. Apo B may be useful in diagnosis and treatment follow-up of some individuals with mild to moderate fasting hypertriglyceridemia (2-10 mmol/L). It is useful to measure Apo B in patients with LDL cholesterol results that are <0.3 mmol/L as part of the diagnosis of abetalipoproteinemia. Patients with Apo B values < 0.1 g/L should be referred to a specialist lipid clinic.
Recommendations: Which Lipids Should be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias? Curr Cardiol Rep. 2018 Aug 17; 20(10):88. doi: 10.1007/s11886-018-1036-1. Additional practice guideline for adults: 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol. 2016; 32 (11): 1263 - 1282 Practice guideline for pediatric/adolescent: Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents Summary Report. 2011; 128 Suppl 5: S213 -- 256 |
| Collection Devices: |
Preferred Devices:
- And -
|
| Specimen Required: |
Serum: 2.0 mL
Pediatric Serum: 0.3 mL
Stability 8 days refrigerated, 2 months frozen |
| Referral: |
Serum: 2.0 mL
Samples must be transferred to an aliquot tube and stored frozen if analysis will not be complete within 48 hours (#110-10-05 Serum/Plasma Separation & Transport)
|
| Requisition: | |
| Reference Values: |
Age <20 yrs: Flagging limit ≥1.00 g/L
Desired: < 0.90 g/L Borderline: 0.90 - 1.00 g/L Increased risk: ≥1.00 g/L
Refer to 2011 NHLBI Guidelines
Age >20 yrs: ≥1.05 g/L
If ApoB ≥1.05 g/L in primary prevention setting for low risk patients (FRS 5.0-9.9%) or intermediate risk patients (FRS 10.0-19.9%), consider therapy. Therapy should also be considered in low risk patients (FRS <10.0%) with ApoB >1.44 g/L.
For additional ApoB thresholds based on risk stratification, refer to the 2021 CCS Guidelines.
|
| Availability: |
Within 1 Week
|
| See Also: | |
| More Information: |